[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Opioid-Induced Constipation Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 189 pages | ID: G7071380EF1EN
Precision Business Insights (PBI)

US$ 4,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Opioid-Induced Constipation Treatment Market Reports

Global Opioid-Induced Constipation Treatment Market are the drugs used for its pain relieving properties in non-cancer and chronic pain. The adverse effects associated with the opioids are decreasing gastrointestinal tract’s motility, making patient’s strain, and making of solid discharges. Furthermore, long-term use of opioids cause harm to the sensory system, limits the release of endogenous opioids such as endorphins. Adults are most likely to prone to opioid-induced constipation owing to less immobility, poor diet, and fluid intake. The symptoms associated with the opioid-induced constipation are included dry and hard tools, leathery feeling, painful defecation, bulged abdomen, and loss of appetite.

The opioid-induced constipation treatment market growing at a significant CAGR due to rise in the aging population using opioid analgesics for chronic pains. Increase in the illicit use of medications, prolonged usage of opioids in the treatment of pain, an increase in the prevalence of cancer is anticipated to boost the global opioid-induced constipation treatment market. Furthermore, launching of newer drugs, growing FDA approvals, positive outcomes in clinical trials, and rise in the healthcare expenditure are expected to propel the opioid-induced constipation treatment market over the forecast period. However, lack of awareness regarding opioid-induced constipation in patients, the absence of treatment innovations, a high cost of newer pharmaceuticals, adverse effects, including nausea, a risk of heart problems and strokes associated with these drugs and unfavorable reimbursement policies expected to hamper the growth of the opioid-induced constipation treatment market.

The opioid-induced constipation treatment market is segmented on the basis of drug type, formulation type, route of administration, and distribution channel

Based on drug type, opioid-induced constipation treatment market has been segmented into the following
  • Peripherally restricted μ-opioid receptor antagonists
  • Non-selective opioid antagonists
  • μ -opioid receptor antagonists
  • Locally acting chloride channel activators
Based on formulation type, opioid-induced constipation treatment market has been segmented into the following
  • Solids
  • Semi-solids
  • Liquids
Based on route of administration, opioid-induced constipation treatment market has been segmented into the following
  • Oral
  • Parenteral (Subcutaneous Injection)
Based on distribution channel, opioid-induced constipation treatment market has been segmented into the following
  • Drugstore
  • Retail pharmacies
  • Hospital pharmacies
The Global Opioid-Induced Constipation Treatment Market is in the growing stage, several players are actively engaged in the development of the opioid-induced constipation treatment market products. Major acquisitions and collaborations among companies to commercialize opioid-induced constipation treatment market products to drive the market growth. For instance, in March 2015, the co-commercialization agreement for Movenpick signed by AstraZeneca and Daiichi Sankyo, and in October 2014, the entry of Takeda and Sucampo into a global licensing, development, and commercialization agreement for Amitiza are expected to boost the global opioid-induced constipation treatment market. Launching of new products, approval of new drugs from various regulatory bodies, and pipeline products under clinical trials are the key factors fuelling the growth of the opioid-induced constipation treatment market. For instance, Linaclotide was approved by the FDA in August 2012 and by the European Medicines Agency for the treatment in adults with constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.

Geographically, Global Opioid-Induced Constipation Treatment Market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the largest share in the opioid-induced constipation treatment market followed by Europe and Asia-Pacific. North America holds the largest share due to expanding the base of opioid-induced constipation patients, According to the American Society of Interventional Pain Physician, in 2013, the U.S. alone was responsible for nearly 80% of the global consumption of opioids. Europe accounts for the significant share in the opioid-induced constipation treatment market owing to increased demand for opioid analgesics in various European countries such as UK, France, Spain, Germany etc. However, growing elderly population in India and China, and rise in healthcare spending are creating the huge growth opportunity for the players in Asia-Pacific region. Apart from that, Latin America and the Middle East are the potential areas for the growth of opioid-induced constipation treatment market because of the increase in opioid-induced constipation sufferers.

Some of the players in the opioid-induced constipation treatment market are GlaxoSmithKline plc (U.K.), AstraZeneca U.K), Pfizer Inc. (U.S.), SLA Pharma AG (U.K.), AIKO Biotechnology, Inc. (U.S.), Cubist Pharmaceuticals (Merck & Co.) (U.S.), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Bayer AG (Germany), Valeant Pharmaceuticals International Inc. (Canada), Abbott Laboratories (U.S.), Purdue Pharma LP (U.S.) Shionogi Inc. (U.S.) and Cosmo Pharmaceuticals N.V. (Ireland) to name a few.

In March 2017, FDA approved Symphonic (Naldemedine) for the treatment of Opioid-Induced Constipation, which was manufactured by Purdue Pharma LP and Shionogi

In March 2016, AstraZeneca announced that it has entered into an agreement with ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., for the rights to Moventig (Naloxegol) in the European Union (EU)

Report Outline:
  • The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
  • The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. EXECUTIVE SUMMARY

2. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET INTRODUCTION

2.1. Global Opioid-Induced Constipation Treatment Market – Taxonomy
2.2. Global Opioid-Induced Constipation Treatment Market –Definitions
  2.2.1. Type of vaccine
  2.2.2. End User

3. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Opioid-Induced Constipation Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Opioid-Induced Constipation Treatment Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Opioid-Induced Constipation Treatment Market – Product Innovations

4. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Peripherally restricted μ-opioid receptor antagonists
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.1.3. Market Opportunity Analysis
5.2. Non-selective opioid antagonists
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.2.3. Market Opportunity Analysis
5.3. μ -opioid receptor antagonists
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.3.3. Market Opportunity Analysis

6. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET FORECAST, BY FORMULATION TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Solids
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.1.3. Market Opportunity Analysis
6.2. Semi-Solids
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis
6.3. Liquids
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.3.3. Market Opportunity Analysis

7. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Oral
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.1.3. Market Opportunity Analysis
7.2. Parenteral
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.2.3. Market Opportunity Analysis

8. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Drug Stores
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.2.3. Market Opportunity Analysis
8.3. Hospital Pharmacies
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.3.3. Market Opportunity Analysis

9. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.1.3. Market Opportunity Analysis
9.2. Europe
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.3.3. Market Opportunity Analysis
9.4. Latin America
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.5.3. Market Opportunity Analysis
9.6. Global Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Type of Vaccine, End User, and Region, 2017 – 2023

10. NORTH AMERICA OPIOID-INDUCED CONSTIPATION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Peripherally restricted μ-opioid receptor antagonists
    10.1.1.2. Non-selective opioid antagonists
    10.1.1.3. μ -opioid receptor antagonists
    10.1.1.4. Locally acting chloride channel activators
  10.1.2. Formulation Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Solids
    10.1.2.2. Semi-Solids
    10.1.2.3. Liquids
  10.1.3. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Oral
    10.1.3.2. Parenteral
  10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Drugstore
    10.1.4.2. Retail pharmacies
    10.1.4.3. Hospital pharmacies
  10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    10.1.5.1. U.S.
    10.1.5.2. Canada
  10.1.6. North America Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2017 – 2023
  10.1.7. North America Opioid-Induced Constipation Treatment Market Dynamics – Trends

11. EUROPE OPIOID-INDUCED CONSTIPATION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Peripherally restricted μ-opioid receptor antagonists
    11.1.1.2. Non-selective opioid antagonists
    11.1.1.3. μ -opioid receptor antagonists
    11.1.1.4. Locally acting chloride channel activators
  11.1.2. Formulation Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Solids
    11.1.2.2. Semi-Solids
    11.1.2.3. Liquids
  11.1.3. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Oral
    11.1.3.2. Parenteral
  11.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.4.1. Drugstore
    11.1.4.2. Retail pharmacies
    11.1.4.3. Hospital pharmacies
  11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.5.1. Germany
    11.1.5.2. UK
    11.1.5.3. France
    11.1.5.4. Spain
    11.1.5.5. Italy
    11.1.5.6. Russia
    11.1.5.7. Poland
    11.1.5.8. Rest of Europe
  11.1.6. Europe Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2017 – 2023
  11.1.7. Europe Opioid-Induced Constipation Treatment Market Dynamics – Trends

12. ASIA-PACIFIC OPIOID-INDUCED CONSTIPATION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Peripherally restricted μ-opioid receptor antagonists
    12.1.1.2. Non-selective opioid antagonists
    12.1.1.3. μ -opioid receptor antagonists
    12.1.1.4. Locally acting chloride channel activators
  12.1.2. Formulation Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Solids
    12.1.2.2. Semi-Solids
    12.1.2.3. Liquids
  12.1.3. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Oral
    12.1.3.2. Parenteral
  12.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Drugstore
    12.1.4.2. Retail pharmacies
    12.1.4.3. Hospital pharmacies
  12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    12.1.5.1. Japan
    12.1.5.2. China
    12.1.5.3. India
    12.1.5.4. ASEAN
    12.1.5.5. Australia & New Zealand
    12.1.5.6. Rest of Asia-Pacific
  12.1.6. Asia-Pacific Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2017 – 2023
  12.1.7. Europe Opioid-Induced Constipation Treatment Market Dynamics – Trends

13. LATIN AMERICA OPIOID-INDUCED CONSTIPATION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Peripherally restricted μ-opioid receptor antagonists
    13.1.1.2. Non-selective opioid antagonists
    13.1.1.3. μ -opioid receptor antagonists
    13.1.1.4. Locally acting chloride channel activators
  13.1.2. Formulation Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Solids
    13.1.2.2. Semi-Solids
    13.1.2.3. Liquids
  13.1.3. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Oral
    13.1.3.2. Parenteral
  13.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.4.1. Drugstore
    13.1.4.2. Retail pharmacies
    13.1.4.3. Hospital pharmacies
  13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.5.1. Brazil
    13.1.5.2. Mexico
    13.1.5.3. Argentina
    13.1.5.4. Venezuela
    13.1.5.5. Rest of Latin America
  13.1.6. Latin America Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2017 – 2023
  13.1.7. Latin America Opioid-Induced Constipation Treatment Market Dynamics – Trends

14. MIDDLE EAST AND AFRICA OPIOID-INDUCED CONSTIPATION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  14.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.1.1. Peripherally restricted μ-opioid receptor antagonists
    14.1.1.2. Non-selective opioid antagonists
    14.1.1.3. μ -opioid receptor antagonists
    14.1.1.4. Locally acting chloride channel activators
  14.1.2. Formulation Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.2.1. Solids
    14.1.2.2. Semi-Solids
    14.1.2.3. Liquids
  14.1.3. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.3.1. Oral
    14.1.3.2. Parenteral
  14.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.4.1. Drugstore
    14.1.4.2. Retail pharmacies
    14.1.4.3. Hospital pharmacies
  14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.5.1. Gulf Cooperation Council (GCC) Countries
    14.1.5.2. Israel
    14.1.5.3. South Africa
    14.1.5.4. Rest of MEA
  14.1.6. MEA Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2017 – 2023
  14.1.7. MEA Opioid-Induced Constipation Treatment Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. GlaxoSmithKline plc (U.K.)
  15.2.2. AstraZeneca U.K)
  15.2.3. Pfizer Inc. (U.S.)
  15.2.4. SLA Pharma AG (U.K.)
  15.2.5. AIKO Biotechnology, Inc. (U.S.)
  15.2.6. Cubist Pharmaceuticals (Merck & Co. Inc.,) (U.S.)
  15.2.7. Takeda Pharmaceutical Company Limited (Japan)
  15.2.8. Boehringer Ingelheim GmbH (Germany)
  15.2.9. Bayer AG (Germany)
  15.2.10. Valeant (Canada)
  15.2.11. Abbott Laboratories (U.S.)
  15.2.12. Purdue Pharma LP (U.S.)
  15.2.13. Shionogi Inc. (U.S.)
  15.2.14. Cosmo Pharmaceuticals N.V. (Ireland)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS


More Publications